GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » PS Ratio

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) PS Ratio : 5.17 (As of May. 15, 2024)


View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, JW (Cayman) Therapeutics Co's share price is $0.30. JW (Cayman) Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.06. Hence, JW (Cayman) Therapeutics Co's PS Ratio for today is 5.17.

The historical rank and industry rank for JW (Cayman) Therapeutics Co's PS Ratio or its related term are showing as below:

JWCTF' s PS Ratio Range Over the Past 10 Years
Min: 3.48   Med: 10.03   Max: 142.55
Current: 6

During the past 6 years, JW (Cayman) Therapeutics Co's highest PS Ratio was 142.55. The lowest was 3.48. And the median was 10.03.

JWCTF's PS Ratio is ranked better than
64.56% of 999 companies
in the Biotechnology industry
Industry Median: 9.04 vs JWCTF: 6.00

JW (Cayman) Therapeutics Co's Revenue per Sharefor the six months ended in Dec. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.06.

During the past 12 months, the average Revenue per Share Growth Rate of JW (Cayman) Therapeutics Co was 16.40% per year.

Back to Basics: PS Ratio


JW (Cayman) Therapeutics Co PS Ratio Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co PS Ratio Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - 142.55 10.96 4.89

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 142.55 - 10.96 - 4.89

Competitive Comparison of JW (Cayman) Therapeutics Co's PS Ratio

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW (Cayman) Therapeutics Co's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's PS Ratio distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's PS Ratio falls into.



JW (Cayman) Therapeutics Co PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

JW (Cayman) Therapeutics Co's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.30/0.058
=5.17

JW (Cayman) Therapeutics Co's Share Price of today is $0.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JW (Cayman) Therapeutics Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.06.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


JW (Cayman) Therapeutics Co PS Ratio Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines

No Headlines